CD133 expression is correlated with chemoresistance and early recurrence of gastric cancer

Journal of Surgical Oncology

Volumn 106, Issue 8, 2012, Pages 999-1004

  Lee, Han Hong ^a   Seo, Kyung Jin ^a   An, Chang Hyeok ^a   Kim, Jeong Soo ^a   Jeon, Hae Myung ^a  

^a The Catholic University of Korea   (South Korea)

Author keywords

CD133 antigen; neoplastic stem cells; recurrence; stomach neoplasms

Indexed keywords

ANTINEOPLASTIC AGENT; CD133 ANTIGEN; CISPLATIN; FLUOROURACIL;

ADJUVANT THERAPY; ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; CANCER ADJUVANT THERAPY; CANCER CLASSIFICATION; CANCER INVASION; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER RESISTANCE; CANCER SURVIVAL; CLINICAL FEATURE; CONTINUOUS INFUSION; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; GASTRECTOMY; GASTROINTESTINAL TOXICITY; HUMAN; IMMUNOHISTOCHEMISTRY; INTESTINE; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NEUROTOXICITY; NEUTROPENIA; OVERALL SURVIVAL; PRIORITY JOURNAL; STOMACH CANCER;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD; DRUG RESISTANCE, NEOPLASM; FEMALE; FOLLOW-UP STUDIES; GLYCOPROTEINS; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASTIC STEM CELLS; PEPTIDES; PROGNOSIS; STOMACH NEOPLASMS; SURVIVAL ANALYSIS; TIME FACTORS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84869500218     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.23178     Document Type: Article

References (33)

1. Kamangar F, Dores GM, Anderson WF,: Patterns of cancer incidence, mortality, and prevalence across five continents: Defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol 2006; 24: 2137-2150.
2. Reya T, Morrison SJ, Clarke MF, Weissman IL,: Stem cells, cancer, and cancer stem cells. Nature 2001; 414: 105-111.
3. Bohl SR, Pircher A, Hilbe W,: Cancer stem cells: Characteristics and their potential role for new therapeutic strategies. Onkologie 2011; 34: 269-274.
4. Miraglia S, Godfrey W, Yin AH, et al.: A novel five-transmembrane hematopoietic stem cell antigen: Isolation, characterization, and molecular cloning. Blood 1997; 90: 5013-5021.
5. Hilbe W, Dirnhofer S, Oberwasserlechner F, et al.: CD133 positive endothelial progenitor cells contribute to the tumour vasculature in non-small cell lung cancer. J Clin Pathol 2004; 57: 965-969.
6. Tirino V, Camerlingo R, Franco R, et al.: The role of CD133 in the identification and characterisation of tumour-initiating cells in non-small-cell lung cancer. Eur J Cardiothorac Surg 2009; 36: 446-453.
7. Hermann PC, Huber SL, Herrler T, et al.: Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell 2007; 1: 313-323.
8. Maeda S, Shinchi H, Kurahara H, et al.: CD133 expression is correlated with lymph node metastasis and vascular endothelial growth factor-C expression in pancreatic cancer. Br J Cancer 2008; 98: 1389-1397.
9. Song W, Li H, Tao K, et al.: Expression and clinical significance of the stem cell marker CD133 in hepatocellular carcinoma. Int J Clin Pract 2008; 62: 1212-1218.
10. Miki J, Furusato B, Li H, et al.: Identification of putative stem cell markers, CD133 and CXCR4, in hTERT-immortalized primary nonmalignant and malignant tumor-derived human prostate epithelial cell lines and in prostate cancer specimens. Cancer Res 2007; 67: 3153-3161.
11. O'Brien CA, Pollett A, Gallinger S, Dick JE,: A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature 2007; 445: 106-110.
12. Horst D, Kriegl L, Engel J, et al.: CD133 expression is an independent prognostic marker for low survival in colorectal cancer. Br J Cancer 2008; 99: 1285-1289.
13. Huh JW, Park YS, Lee JH, et al.: CD133 mRNA expression and microsatellite instability in colorectal carcinoma. J Surg Oncol 2010; 102: 765-770.
14. Singh SK, Clarke ID, Terasaki M, et al.: Identification of a cancer stem cell in human brain tumors. Cancer Res 2003; 63: 5821-5828.
15. Singh SK, Hawkins C, Clarke ID, et al.: Identification of human brain tumour initiating cells. Nature 2004; 432: 396-401.
16. Qiao XT, Gumucio DL,: Current molecular markers for gastric progenitor cells and gastric cancer stem cells. J Gastroenterol 2011; 46: 855-865.
17. Smith LM, Nesterova A, Ryan MC, et al.: CD133/prominin-1 is a potential therapeutic target for antibody-drug conjugates in hepatocellular and gastric cancers. Br J Cancer 2008; 99: 100-109.
18. Boegl M, Prinz C,: CD133 expression in different stages of gastric adenocarcinoma. Br J Cancer 2009; 100: 1365-1366 author reply 1367.
19. Joo YE, Chung IJ, Park YK, et al.: Expression of cyclooxygenase-2, p53 and Ki-67 in gastric cancer. J Korean Med Sci 2006; 21: 871-876.
20. Kojima M, Ishii G, Atsumi N, et al.: Immunohistochemical detection of CD133 expression in colorectal cancer: A clinicopathological study. Cancer Sci 2008; 99: 1578-1583.
21. Ishigami S, Ueno S, Arigami T, et al.: Prognostic impact of CD133 expression in gastric carcinoma. Anticancer Res 2010; 30: 2453-2457.
22. Yu JW, Zhang P, Wu JG, et al.: Expressions and clinical significances of CD133 protein and CD133 mRNA in primary lesion of gastric adenocarcinoma. J Exp Clin Cancer Res 2010; 29: 141.
23. Zhao P, Li Y, Lu Y,: Aberrant expression of CD133 protein correlates with Ki-67 expression and is a prognostic marker in gastric adenocarcinoma. BMC Cancer 2010; 10: 218.
24. Japanese Gastric Cancer Association: Japanese Classification of Gastric Carcinoma-2nd English Edition. Gastric Cancer 1998; 1: 10-24.
25. Watanabe H, Jass JR, Sobin LH,: Histological typing of esophageal and gastric tumors: WHO international histological classification of tumors. 2nd edition Berlin: Springer; 1990.
26. Fukamachi H, Shimada S, Ito K, et al.: CD133 is a marker of gland-forming cells in gastric tumors and Sox17 is involved in its regulation. Cancer Sci 2011; 102: 1313-1321.
27. Liu G, Yuan X, Zeng Z, et al.: Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma. Mol Cancer 2006; 5: 67.
28. Ma S, Lee TK, Zheng BJ, et al.: CD133+ HCC cancer stem cells confer chemoresistance by preferential expression of the Akt/PKB survival pathway. Oncogene 2008; 27: 1749-1758.
29. Eramo A, Lotti F, Sette G, et al.: Identification and expansion of the tumorigenic lung cancer stem cell population. Cell Death Differ 2008; 15: 504-514.
30. Baba T, Convery PA, Matsumura N, et al.: Epigenetic regulation of CD133 and tumorigenicity of CD133+ ovarian cancer cells. Oncogene 2009; 28: 209-218.
31. Dean M, Fojo T, Bates S,: Tumour stem cells and drug resistance. Nat Rev Cancer 2005; 5: 275-284.
32. Zhou S, Schuetz JD, Bunting KD, et al.: The ABC transporter Bcrp1/ABCG2 is expressed in a wide variety of stem cells and is a molecular determinant of the side-population phenotype. Nat Med 2001; 7: 1028-1034.
33. Ferrandina G, Petrillo M, Bonanno G, Scambia G,: Targeting CD133 antigen in cancer. Expert Opin Ther Targets 2009; 13: 823-837.